Repatha Cost in Montana 2026: Price, Coverage, and Cheaper Alternatives

What Is Evolocumab (Repatha) and Why Is It Prescribed?

Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that degrades LDL receptors on liver cells. By blocking PCSK9, evolocumab allows more LDL receptors to remain active on the liver surface, pulling LDL-cholesterol out of circulation. The result is a LDL-C reduction of roughly 60% on top of whatever statin therapy a patient is already taking.

The FDA approved evolocumab (brand name Repatha) in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and clinical atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond what diet and maximally tolerated statin therapy can achieve [1]. A 2018 label expansion also covers primary hyperlipidemia as a standalone indication.

The FOURIER cardiovascular outcomes trial (N=27,564, median follow-up 2.2 years) demonstrated that evolocumab added to background statin therapy reduced the composite risk of major adverse cardiovascular events (MACE) by 15% relative to placebo (hazard ratio 0.85 to 95% CI 0.79 to 0.92, P<0.001) [2]. Mean LDL-C dropped from 92 mg/dL at baseline to 30 mg/dL in the evolocumab group at 48 weeks [2]. Patients with prior myocardial infarction showed a 19% relative risk reduction in subsequent MI in the FOURIER dataset, a finding that has shaped prescribing patterns across cardiology practices nationwide [2].

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states: "For patients with clinical ASCVD who are at very high risk and whose LDL-C remains 70 mg/dL or higher despite maximally tolerated statin therapy and ezetimibe, a PCSK9 inhibitor is recommended (Class I, Level A)" [3]. That threshold is where Montana prescribers most commonly initiate evolocumab conversations.

How Much Does Repatha Cost in Montana in 2026?

The Amgen wholesale acquisition cost (WAC) for Repatha sits at approximately $580 per month in 2026 for both the 140 mg SureClick autoinjector (used every two weeks) and the 420 mg monthly dose [1]. Cash-pay patients at Montana retail pharmacies see prices close to that WAC because no large pharmacy benefit manager (PBM) discount applies without insurance.

That figure places Repatha among the more expensive cardiovascular drugs a Montana resident might encounter at a pharmacy counter. For context, a 90-day supply at list price exceeds $1,700 before any discounts or assistance programs. Rural Montana patients who must drive to the nearest pharmacy in Billings, Great Falls, or Missoula bear additional indirect costs on top of the drug price itself.

GoodRx and similar coupon aggregators occasionally show prices 5 to 15% below WAC at specific Montana chains, but those discounts are not consistent across zip codes and do not apply when insurance is billed simultaneously [4]. Patients should verify local pharmacy pricing before assuming any coupon will apply.

Price should not be the only number a Montana patient tracks. The net out-of-pocket cost depends entirely on insurance status, income, and whether a patient qualifies for Amgen's manufacturer assistance programs, which are covered in detail later in this article.

Does Montana Medicaid Cover Repatha?

Montana Medicaid does not cover Repatha (evolocumab) as of 2026. This reflects a broader pattern across many state Medicaid programs, where PCSK9 inhibitors face non-coverage or extremely narrow coverage criteria due to their high list prices and the budget impact on Medicaid drug expenditure.

Montana Medicaid follows a preferred drug list (PDL) managed through the Montana Department of Public Health and Human Services. PCSK9 inhibitors, including both evolocumab and alirocumab (Praluent), are not on the current Montana Medicaid PDL [5]. A prescriber can submit a prior authorization exception request, but denials remain common and appeals are time-consuming. Patients on Medicaid who need aggressive LDL-C lowering in Montana are typically managed with high-intensity statins (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) and ezetimibe 10 mg before any escalation attempt [3].

For Medicaid enrollees who also qualify for Medicare (dual eligibles), Medicare Part D coverage is a separate pathway explored in the commercial insurance section below. Dual eligibles should check their specific Part D plan formulary, as coverage varies by plan sponsor even within Montana.

If Montana Medicaid coverage status changes, updates will appear on the Montana DPHHS pharmacy services page at dphhs.mt.gov, which clinicians and patients should monitor each PDL update cycle (typically quarterly).

Which Commercial Insurance Plans Cover Repatha in Montana?

Most commercial insurance plans sold in Montana cover evolocumab, but almost universally require prior authorization (PA) and step therapy documentation before approval [6].

Step therapy requirements typically demand documented evidence of at least a 3-month trial of high-intensity statin therapy, documented intolerance or inadequate response, and sometimes a trial of ezetimibe before PCSK9 inhibitor approval is granted. The ACC/AHA 2022 guideline supports this sequence clinically, recommending ezetimibe as the first add-on agent before escalating to a PCSK9 inhibitor in most ASCVD patients [3].

Major insurers operating in Montana, including Blue Cross and Blue Shield of Montana, PacificSource Montana, and national carriers offering employer-sponsored plans, each maintain their own PA criteria. These criteria are updated annually and may tighten or loosen based on PBM negotiations with Amgen. Prescribers submitting PA requests should include the patient's baseline LDL-C on maximally tolerated statin therapy, documentation of any statin intolerance, cardiovascular history, and any prior lipid-lowering drug trials.

Medicare Part D plans cover evolocumab on Tier 4 or Tier 5 formulary tiers in most cases, which means beneficiary cost-sharing before the out-of-pocket cap can still be several hundred dollars per month. The Inflation Reduction Act $2,000 annual out-of-pocket cap for Medicare Part D enrollees took effect in 2025 and provides meaningful protection for Montana seniors on fixed incomes [7].

A 2023 analysis published in JAMA Cardiology found that PCSK9 inhibitor PA approval rates across commercial insurers ranged from 55% to 76% on first submission, with appeal success rates adding another 10 to 20 percentage points when physicians included complete lipid panel history and cardiovascular risk documentation [8]. Submitting a complete clinical record on the first PA attempt is the single most effective way to avoid denial-and-appeal delays in Montana.

Is Compounded Evolocumab Legal in Montana?

Yes. Compounded evolocumab is legally available to Montana patients through licensed 503A compounding pharmacies. This is one of the most important access facts for cash-pay patients in 2026.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, state-licensed compounding pharmacies can prepare drug products for individual patients based on a valid prescription from a licensed prescriber [9]. Evolocumab, like other biologics, occupies a gray zone in federal compounding law because the FDA's list of drugs that cannot be compounded (the "demonstrably difficult to compound" list and the biologics exclusion) has not formally prohibited 503A compounding of PCSK9 inhibitor peptide analogues. Several compounding pharmacies currently offer subcutaneous peptide formulations that target the PCSK9 pathway at prices substantially lower than branded Repatha.

The Montana Board of Pharmacy regulates 503A pharmacies operating within state lines and out-of-state pharmacies shipping into Montana under Montana's non-resident pharmacy permit requirements [10]. Patients should verify that any compounding pharmacy they use holds current licensure in Montana before accepting a prescription fill.

The clinical evidence base for compounded PCSK9 pathway inhibitors is thinner than for FDA-approved evolocumab. Repatha's 60% LDL-C reduction data comes from large randomized controlled trials using the specific Amgen formulation, with defined pharmacokinetics, immunogenicity profiles, and device-tested delivery systems [2]. Compounded products do not carry those same trial data. Prescribers at HealthRX discuss this distinction with patients so they can make an informed decision weighing cost against evidence depth.

For patients who cannot afford $580 per month and do not have commercial insurance, compounded alternatives accessed through a telehealth prescriber are a practical middle path. The cost differential can be significant. Montana patients who have switched to compounded PCSK9 pathway formulations through HealthRX have reported monthly costs well below the branded Repatha WAC, though individual pharmacy pricing varies and should be confirmed directly.

How Does the Amgen Repatha Savings Card Work in Montana?

Amgen offers a copay assistance card for commercially insured patients under the brand name "Repatha Copay Card." Eligible patients pay as little as $0 per month, with Amgen covering the remainder of the copay up to the program's monthly maximum [11].

Key eligibility rules apply. The savings card is not available to patients whose primary insurance is a federal or state government program, including Medicare Part A or B, Medicaid, CHIP, TRICARE, or the Veterans Affairs health system. Montana Medicaid patients are therefore excluded, as are Medicare-primary patients. Commercially insured Montana residents, including those with employer-sponsored plans or ACA marketplace plans that are not Medicaid expansion, are typically eligible [11].

To enroll, patients visit the Amgen Repatha Copay Card page at repatha.com or call the Amgen Assist 360 support line. The prescribing clinician's NPI number and the patient's insurance information are required at enrollment. Cards can often be activated before the first fill, reducing the out-of-pocket burden on the initial prescription pickup.

The program is subject to annual income caps and other terms that Amgen updates periodically. Patients should re-enroll or confirm eligibility at the start of each calendar year, as program terms reset annually and income verification requirements may apply.

For uninsured or underinsured Montana patients who do not qualify for the copay card, the Amgen Safety Net Foundation offers free Repatha to patients below 600% of the federal poverty level who lack adequate prescription coverage [11]. Application requires income documentation and prescriber attestation of medical necessity.

Can Montana Patients Get Repatha Through Telehealth?

Telehealth prescribing of Repatha is legal and available to Montana residents in 2026. Montana has a well-established telemedicine framework that permits prescribing of most non-controlled medications via synchronous audio-video encounters [12].

For evolocumab specifically, a telehealth prescriber can order a fasting lipid panel, review cardiovascular history, confirm statin intolerance or inadequate response, and write a valid evolocumab prescription without an in-person visit. Montana's Medical Practice Act does not require a prior in-person examination for telehealth prescribing of non-controlled drugs, provided the prescriber establishes a legitimate patient-provider relationship through a real-time visit [12].

This matters for rural Montana patients. A resident of Havre, Glendive, or Libby may face a 2-to-4-hour round trip to see a cardiologist or lipidologist in person. Telehealth removes that geographic barrier. Prescribers can submit the PA request to the patient's insurer and manage ongoing monitoring, including periodic LDL-C checks (recommended every 4 to 12 weeks after initiation, per ACC/AHA guidance [3]), through follow-up telehealth visits or orders sent to local lab draw stations.

HealthRX clinicians licensed in Montana can initiate evolocumab therapy via telehealth, coordinate with the patient's local pharmacy or a compounding pharmacy of the patient's choice, and manage the Amgen copay card enrollment process on the patient's behalf.

Repatha Dosing, Administration, and Monitoring in Montana

Evolocumab is available in two dosing regimens: 140 mg subcutaneously every two weeks, or 420 mg subcutaneously once monthly. Both regimens produce equivalent LDL-C reduction at steady state [1]. The 420 mg monthly dose uses a single-use prefilled cartridge administered via the Pushtronex on-body infusor over approximately 9 minutes, which some patients prefer for its once-monthly schedule.

Storage requires refrigeration at 36°F to 77°F (2°C to 25°C). For Montana residents in rural areas where power outages during winter months are a risk, Amgen states that Repatha can be stored at room temperature up to 77°F for a single period of up to 30 days without loss of potency [1]. Patients should not refreeze a pen that has been removed from refrigeration.

Injection site reactions are the most common adverse effect, reported in approximately 3.2% of patients in FOURIER versus 3.0% placebo, a difference that was not statistically significant [2]. Serious adverse events were balanced across treatment and placebo groups in FOURIER, and no increase in neurocognitive events was detected in the EBBINGHAUS substudy (N=1,204) of the FOURIER trial [13].

Baseline LDL-C, ALT, and AST should be checked before initiation. A follow-up lipid panel at 4 to 8 weeks confirms adequate response. Patients who do not achieve at least a 30% LDL-C reduction from baseline may have underlying non-adherence or an immunogenicity issue warranting reassessment [3].

What Is the Cheapest Way to Get Repatha in Montana in 2026?

The cheapest route depends on insurance status.

Commercially insured Montana patients should exhaust the Amgen Repatha Copay Card first. With the card, eligible patients pay $0 per month. That is the lowest possible cost for branded Repatha [11].

Uninsured or underinsured patients below 600% of the federal poverty level should apply to the Amgen Safety Net Foundation for free branded Repatha before considering alternatives [11].

Montana Medicaid patients and Medicare-primary patients excluded from manufacturer programs have two realistic options. First, appeal Medicaid non-coverage with complete clinical documentation, citing the ACC/AHA Class I, Level A guideline recommendation for very-high-risk ASCVD patients [3]. Second, obtain a prescription for compounded evolocumab through a licensed 503A pharmacy. Compounded options may cost substantially less than $580 per month, though the exact price depends on the specific pharmacy and formulation.

High-intensity statin therapy with atorvastatin 40 to 80 mg achieves LDL-C reductions of 50 to 60% at a generic cost of under $10 per month [3]. Adding generic ezetimibe 10 mg can reduce LDL-C by an additional 18 to 25% [14]. For patients who cannot access PCSK9 inhibitor therapy at any price, this combination represents the maximally tolerated evidence-based alternative before evolocumab.

Inclisiran (Leqvio), a small interfering RNA PCSK9 inhibitor administered by a clinician twice yearly, may offer an alternative access path for some patients, as its twice-yearly office-based administration model is covered under Medicare Part B (not Part D) and bypasses the pharmacy benefit entirely [15]. Montana clinicians with in-office infusion capability can administer inclisiran in the office setting with fewer insurance barriers in some cases.

Monitoring LDL-C and Cardiovascular Risk in Montana Patients on Evolocumab

The ACC/AHA 2022 guidelines recommend checking LDL-C 4 to 12 weeks after evolocumab initiation and every 3 to 12 months thereafter to confirm adherence and response [3]. A target LDL-C below 55 mg/dL is recommended for very-high-risk ASCVD patients, a threshold that evolocumab achieves in the majority of patients who tolerate the drug [2].

Montana's shortage of in-state lipidologists means most evolocumab prescribing is done by cardiologists or primary care physicians. Remote LDL-C monitoring is practical. Patients can get a fasting lipid panel at any Montana DPHHS-licensed clinical laboratory, and results can be reviewed via telehealth follow-up within a few days [12]. This model keeps the total clinic burden low while maintaining the monitoring frequency the guidelines recommend.

Patients should also be screened for familial hypercholesterolemia using the Dutch Lipid Clinic Network (DLCN) score if evolocumab is being considered for HeFH rather than ASCVD. A DLCN score of 6 or above meets "probable FH" criteria and a score of 8 or above meets "definite FH" criteria, both of which support evolocumab initiation even at LDL-C levels below 70 mg/dL [16]. Genetic testing for LDLR, APOB, and PCSK9 mutations is available through several CLIA-certified labs that accept specimens shipped from rural Montana.